Bayer/€BAYN
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Bayer
Bayer AG, operating under the ticker BAYN, is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863, the company is headquartered in Leverkusen, Germany, and operates in several sectors, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer is known for developing new molecules for use in innovative products and solutions to improve the health of humans, animals, and plants.
Ticker
€BAYN
Sector
Primary listing
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
90,885
ISIN
DE000BAY0017
Website
Bayer Metrics
BasicAdvanced
€26B
-
-€3.32
0.98
€0.11
0.42%
Price and volume
Market cap
€26B
Beta
0.98
52-week high
€30.33
52-week low
€18.38
Average daily volume
3.3M
Dividend rate
€0.11
Financial strength
Current ratio
1.246
Quick ratio
0.791
Long term debt to equity
107.483
Total debt to equity
120.88
Interest coverage (TTM)
3.41%
Profitability
EBITDA (TTM)
8,432
Gross margin (TTM)
56.28%
Net profit margin (TTM)
-6.98%
Operating margin (TTM)
10.05%
Effective tax rate (TTM)
-4.81%
Revenue per employee (TTM)
€510,000
Management effectiveness
Return on assets (TTM)
2.55%
Return on equity (TTM)
-9.49%
Valuation
Price to revenue (TTM)
0.557
Price to book
0.8
Price to tangible book (TTM)
-1.43
Price to free cash flow (TTM)
4.485
Free cash flow yield (TTM)
22.30%
Free cash flow per share (TTM)
588.65%
Dividend yield (TTM)
0.42%
Forward dividend yield
0.42%
Growth
Revenue change (TTM)
-0.92%
Earnings per share change (TTM)
4.57%
3-year revenue growth (CAGR)
0.13%
10-year revenue growth (CAGR)
0.85%
3-year earnings per share growth (CAGR)
14.02%
10-year earnings per share growth (CAGR)
-1.93%
3-year dividend per share growth (CAGR)
-61.97%
10-year dividend per share growth (CAGR)
-26.05%
What the Analysts think about Bayer
Analyst ratings (Buy, Hold, Sell) for Bayer stock.
Bulls say / Bears say
Bayer's first-quarter adjusted EBITDA fell by 7.4% to €4.09 billion, surpassing market expectations of €3.75 billion, indicating resilience in its pharmaceutical segment. (reuters.com)
The U.S. FDA Commissioner reassured Bayer and other pharmaceutical executives of maintaining timely drug reviews, supporting the company's pipeline progression. (reuters.com)
Bayer's new drugs, Nubeqa and Kerendia, contributed significantly to U.S. sales, totaling €680 million in the first quarter, reflecting strong market acceptance. (reuters.com)
Bayer's shares hit a 20-year low after forecasting a decline in 2025 earnings due to weak agricultural markets, raising concerns about future profitability. (usnews.com)
The company is considering filing for bankruptcy for its Monsanto unit to manage ongoing Roundup litigation, highlighting significant legal and financial challenges. (reuters.com)
Bayer plans to exit the U.S. seed treatment equipment business and scale back German agriculture activities due to competitive pressures, indicating potential revenue declines. (reuters.com, reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Bayer Financial Performance
Revenues and expenses
Bayer Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bayer stock?
Bayer (BAYN) has a market cap of €26B as of June 26, 2025.
What is the P/E ratio for Bayer stock?
The price to earnings (P/E) ratio for Bayer (BAYN) stock is 0 as of June 26, 2025.
Does Bayer stock pay dividends?
Yes, the Bayer (BAYN) stock pays dividends to shareholders. As of June 26, 2025, the dividend rate is €0.11 and the yield is 0.42%. Bayer has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Bayer dividend payment date?
The next Bayer (BAYN) dividend payment date is unconfirmed.
What is the beta indicator for Bayer?
Bayer (BAYN) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.